(Q24632726)

2

0 references

Yili Pritchett

3

0 references

Tushar Garimella

4

0 references

Walid Abi-Saab

5

0 references

George Apostol

6

0 references

James J McGough

7

0 references

Mario D Saltarelli

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

8

0 references

language of work or name

English

0 references

publication date

February 2013

0 references

published in

Neuropsychopharmacology

0 references

volume

38

0 references

issue

3

0 references

page(s)

405-13

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Neuronal nicotinic receptors: from structure to pathology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Methylphenidate significantly improves declarative memory functioning of adults with ADHD.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Primary care treatment of attention-deficit/hyperactivity disorder.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Impact of comorbidity in adults with attention-deficit/hyperactivity disorder.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Effects of nicotinic stimulation on cognitive performance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3547191

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Cognitive enhancement in man with ispronicline, a nicotinic partial agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

The Effect of Stimulant Treatment for ADHD on Later Substance Abuse and the Potential for Medication Misuse, Abuse, and Diversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

The relationship between satisfaction with life, ADHD symptoms, and associated problems among university students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Does Prolonged Therapy With a Long-Acting Stimulant Suppress Growth in Children With ADHD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2012.194

The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23032073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NPP.2012.194

1 reference

Dimensions Publication ID

1021756961

0 references

1 reference

1 reference

PubMed publication ID

23032073

1 reference